Quality of previous diabetes care among patients receiving services at ophthalmology hospitals in Mexico

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 28, Issue 6, 2010, Pages 440-445

  Rodríguez Saldana, Joel ^a   Rosales Campos, Andrea C ^a   León, Carmen B Rangel ^a   Vázquez Rodríguez, Laura I ^a   Martínez Castro, Francisco ^b   Piette, John D ^c  

^a Centro Multidisciplinario de Diabetes de la Ciudad de México   (Mexico)

^b Sociedad Mexicana de Medicina Nucl   (Mexico)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diabetes complications; Diabetes mellitus; Diabetic retinopathy; Mexico; Quality of health care; Type 2

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BLOOD; DIABETES; EYE DISEASE; FASTING; GLUCOSE; HEALTH EDUCATION; HEALTH POLICY; HEALTH SERVICES; HEALTH STATUS; HEALTH SURVEY; HOSPITAL SECTOR; PUBLIC ACCESS; SOCIAL SECURITY;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COUNSELING; DIABETIC RETINOPATHY; ECONOMICS; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SURVEY; HOSPITAL; HUMAN; MALE; MEXICO; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOLOGY; PATIENT EDUCATION; RETROSPECTIVE STUDY; RISK FACTOR; SOCIAL SECURITY; SOCIOECONOMICS; STATISTICS;

AGED; BLOOD GLUCOSE; COUNSELING; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HEALTH EXPENDITURES; HEALTH SURVEYS; HOSPITALS, SPECIAL; HOSPITALS, URBAN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEXICO; MIDDLE AGED; OPHTHALMOLOGY; PATIENT EDUCATION AS TOPIC; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIAL SECURITY; SOCIOECONOMIC FACTORS;

MEXICO [NORTH AMERICA];

EID: 79551711566     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-31 (Pubitemid 28405191)
2. Sistema Nacional de Información en Salud (SINAIS). Defunciones 2007. Available from: http://sinais.salud.gob.mx/mortalidad/index.html. Accessed on 15 June 2009.
3. Dirección General de Epidemiología. Compendio de Anuarios de Morbilidad 1984-2007. Available from: http://www.dgepi.salud.gob.mx/infoepi/ index.htm Accessed on 15 June 2009.
4. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, et al. Encuesta Nacional de Salud 2000. Tomo 2: La salud de los adultos. Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública; 2003.
5. Aguilar-Salinas CA, Velásquez Monroy O, Gómez-Pérez FJ, González-Chávez A, Lara-Esqueda A, Molina-Cuevas V, et al. Characteristics of patients with type 2 diabetes in México. Results from a large population-based nationwide survey. Diabetes Care. 2003;26(7):2021-6. (Pubitemid 41184245)
6. Barceló A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas. Rev Panam Salud Publica. 2001;10(5):300-8. (Pubitemid 33143952)
7. Arredondo A, Zúñiga A. Economic consequences of epidemiological changes in diabetes in middle-income countries: the Mexican case. Diabetes Care. 2004;27(1):104-9. (Pubitemid 38196717)
8. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003; 81(1):19-27. (Pubitemid 36168649)
9. Wagner EH, Bennett SM, Austin BT, Greene SM, Schaefer JK, Vonkorff M. Finding common ground: patient centeredness and evidence-based chronic illness care. J Alt Comp Med. 2005;11(1)(Suppl 1):S-7-S-15. (Pubitemid 43004964)
10. Secretaría de Salud México. Rendición de cuentas en salud 2008. México: Secretaría de Salud México; 2009.
11. Lopez-Maldonado FJ, Reza-Albarran AA, Suarez OJ, Villa AR, Rios-Vaca A, Gomez-Perez FJ, et al. Degree of control of cardiovascular risk factors among a patient population with diabetes mellitus type 1 and 2. Gac Med Mex. 2009;145(1):1-6.
12. Frenk J, Sepúlveda J, Gómez-Dantés O, Knaul F. Evidence-based policy: three generations of reform in Mexico. Lancet. 2003;362:1667-71. (Pubitemid 37443538)
13. Sosa-Rubí SG, Galárraga O, López-Ridaura R. Diabetes treatment and control: the effect at public health insurance for the poor in Mexico. Bull World Health Organ. 2009;87: 512-9.
14. González-Villalpando C, López-Ridaura R, Campuzano JC, González-Villalpando ME. The status of diabetes care in Mexican population: are we making a difference? Results of the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52(Suppl 1): S36-43.
15. World Health Organization. Visual impairment and blindness, 2009. Available from: http://www.who.int/mediacentre/factsheets/fs282/en/print.html Accessed on 5 August 2009.
16. Rodriguez-Saldana J, Morales de Teresa M, Rosales-Campos, AC, Clark Jr CM, Mazze RM, Strock E. Effectiveness of Staged Diabetes Management on the quality of diabetes care in Mexico. Practical Diabetes Int. 2010; 27(4):242-7.
17. Service FJ, O'Brien PC. The relation of gly-caemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia. 2001;44(12):1215-20. (Pubitemid 33010497)
18. Kohner EM. Microvascular disease: what does the UKPDS tell us about diabetic reti-nopathy? Diabet Med. 2008;25(1)(Suppl. 2): 20-4. (Pubitemid 352020101)
19. The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44(8):968-83.
20. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563-9.
21. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinop-athy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-9.
22. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Opthalmol. 2008;126(12):1707-15.
23. World Health Organization. Priority eye disease, 2009. Available from: http://www.who.int/blindness/causes/priority/en/print.html. Accessed on 5 August 2009.
24. World Health Organization. Prevention of blindness from diabetes mellitus: report of a WHO consultation in Geneva, Switzerland, 9-11 November 2005. Geneva: WHO; 2006.
25. Prasad S, Ahmad A, Kamath GG, Phillips RP, Bowen-Jones D. Screening for diabetic reti-nopathy. Pract Diabetes Int. 1999;16(1):51-5.
26. Baker R, Grimshaw JR, Thompson JR, Wilson A. Services for diabetic retinopathy screening in England and Wales: a survey of ophthalmologists. Practical Diabetes Int. 1999;16(1):33-4. (Pubitemid 29229568)
27. Garvican L, Clowes J, Gillow T. Preservation of sight in diabetes: developing a national risk reduction programme. Diabet Med. 2000; 17(9):627-34.
28. Misra A, Bachmann MO, Greenwood RH, Jenkins C, Shaw A, Baraka O, Flatman M, Jones CD. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetes retinopathy screening programme. Diabet Med. 2009; 26(10):1040-7.
29. Rodriguez-Villalobos E, Ramirez-Barba E, Cervantes-Aguayo F. Frecuencia y oportu-nidad del diagnóstico de retinopatía dia-bética. Salud Publica Mex. 1994;36:275-80.